South Korea places order for 8x8 air defence guns
The Defense Acquisition Program Administration (DAPA) in South Korea announced on 27 June that it has sealed a contract with Hanwha Defense for its 8x8 air defence system.
The deal is worth KRW250 billion ($207.7 million), though the number of self-propelled antiaircraft guns (SPAAG) ordered was not disclosed. However, Shephard previously reported that the Republic of Korea Army (ROKA) requires some 270 wheeled SPAAGs.
The K808-based 8x8 chassis is manufactured by Hyundai Rotem, whereas the twin 30mm weapon system and other equipment is the responsibility of Hanwha Defense. Its official nomenclature has not been revealed yet.
The new system
Already have an account? Log in
Want to keep reading this article?
Read this Article
Get access to this article with a Free Basic Account
- Original curated content, daily across air, land and naval domains
- 2 free stories per week
- Daily news round-up email service
- Access to all Decisive Edge email newsletters
Unlimited Access
Access to all our premium news as a Premium News 365 Member. Corporate subscriptions available.
- Original curated content, daily across air, land and naval domains
- 14-day free trial (cancel at any time)
- Unlimited access to all published premium news
More from Land Warfare
-
![Lockheed Martin to increase PAC-3 MSE production by 70%]()
Lockheed Martin to increase PAC-3 MSE production by 70%
The company manufactured 380 missiles in 2023 and plans to build 650 missiles per year from 2027.
-
![Latvia orders more Patria 6x6 vehicles]()
Latvia orders more Patria 6x6 vehicles
The first Latvian-made Common Armoured Vehicle System (CAVS) 6x6 armoured personnel carrier was delivered to the Latvian National Armed Forces (NAF) in August, and more than 200 vehicles are expected to be delivered by 2029.
-
![Canadian tech firm makes promise to increase precision and longevity of weapons]()
Canadian tech firm makes promise to increase precision and longevity of weapons
Supplied by Paradigm Shift, EPVD technology has undergone trials with the US and Canadian services.
